RxDoctor Payments Data

Robert Guzoujian, MD

Internal Medicine · Clovis, CANPI 1972584472

Payments from drug & device makers

$2,697in general payments, 2019–2025

Across 145 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$566
  • AbbVie$274
  • Novo Nordisk$237
  • GSK$222
  • Lilly USA, LLC$192
  • Pfizer$165
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,697100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,697 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$130,138
Medicare patients
406
Services billed
1,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$86,666
FarxigaDapagliflozin Propanediol39$48,214
EliquisApixaban50$35,472
JanuviaSitagliptin Phosphate21$27,335
WegovySemaglutide14$18,454
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,087
Bydureon BciseExenatide Microspheres13$10,583
Repatha SureclickEvolocumab13$6,880
Spiriva HandihalerTiotropium Bromide11$5,834
Rosuvastatin Calcium430$5,078
Metoprolol Succinate319$4,644
SynthroidLevothyroxine Sodium81$4,473
Levothyroxine Sodium401$4,094
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$3,989
Hysingla ErHydrocodone Bitartrate11$3,913

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$237$105,11994 claims
AstraZenecaFarxiga$566$48,21439 claims
PfizerEliquis$165$35,47250 claims
MerckJanuvia$17$27,33521 claims
GSKTrelegy Ellipta$222$11,08717 claims
AbbVieSynthroid$274$4,47381 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Clovis

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →